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Tocotrienol: An Underrated 




Vitamin E was first discovered as a fertility factor in 1922 in the laboratory 
of Herbert McLean Evans, a scientist and anatomist. Following this discovery, it 
was extensively researched and found to possess a potent antioxidant property. It 
soon dawned that the family of vitamin E has eight members: four tocopherols, 
namely α-, β-, δ- and γ-tocopherol; and four tocotrienols in the form of α-, β-, 
δ- and γ-tocotrienols. This chapter discusses this rather unknown and underrated 
isomer of vitamin E with unsurpassed health benefits: tocotrienols. Until recently, 
tocotrienols rarely figured in vitamin E research in spite of their relative superiority 
to tocopherol coupled with their abundant presence in palm oil. In fact, since palm 
oil contains about 70% of all tocotrienol homologues, it would be no exaggeration 
to call it nature’s best kept secret, if not the most promising natural substance in 
influencing health and disease. While highlighting the wonders of tocotrienols as a 
safe and efficacious product, this chapter offers a panoramic view of recent research 
into tocotrienols that demonstrates their undeniable benefits in conferring protec-
tion against cancer as well as a whole litany of ailments including cardiovascular, 
metabolic, autoimmune, bone and neurological diseases. Admittedly, many of these 
researches were conducted in the laboratory, with some preclinical trials translated 
into clinical trials. Nonetheless, it is hoped that more randomised clinical trials will 
be carried out on a global scale in the near future. From the vessels in the heart to 
the neurons in the brain, tocotrienols have the extraordinary potential to be the 
future of vitamin E research.
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1. Introduction
Vitamin E, an important nutrient in the human diet that is readily available in 
lipid-rich plant products, is well known for its antioxidant properties with multiple 
health benefits. Historically, drug discovery researches have focused on natural 
products that abound in biological compounds with pharmacologic properties [1]. 
The discovery of vitamin E began in 1922 when Herbert Evans and Katherine Bishop 
[2] isolated an uncharacterised fat-soluble compound (which they termed ‘substance 
X’) from green leafy vegetables that they imagined might play a role in fertility. 
When the compound was finally identified in 1924, it was named tocopherol — 
derived from the Greek word tokos meaning childbirth and pheros which means to 
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bring forth [3]. Vitamin E was rediscovered as ‘factor 2 antioxidant’ in 1965 [4]. Not 
surprisingly, as the major isoform of Vitamin E ever identified, α-tocopherol was 
thrust into the limelight while its sisters were ignored. Tocopherol is regarded as the 
most biologically active and potent antioxidant currently in existence. However, 
recent studies have shown that tocotrienols may have superior anti-oxidant [5], anti-
inflammatory [6], anti-cholesterolaemic, [7–11] anti-cancer [12, 13], anti-diabetic 
[14–16], anti-atherogenic [17, 18], blood pressure lowering, [19, 20] and neuropro-
tective effects [21–23]. Unfortunately, despite the recent interest in tocotrienols, it 
comprises only 3% of all vitamin E research papers listed in PubMed [24].
2. Biochemical properties of vitamin E isoforms
Generally, vitamin E is classified into tocopherols and tocotrienols, and there 
are eight isoforms altogether: α-, β-, γ-, and δ-tocopherol, and α-, β-, γ-, and 
δ-tocotrienol. Structurally, they are very similar and possess a chromanol head 
formed by phenolic and heterocyclic rings, and a phenyl tail [25]. Designation as α-, 
β-, γ- or δ-tocopherol or tocotrienols is dependent on the methyl substitutions on 
Figure 1. 
The different structures between tocopherols and tocotrienols.
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the phenolic ring [26]. The main difference between the two groups is that tocoph-
erols have a long-saturated carbon side-chain with chiral centres, whereas tocot-
rienols possess three unsaturated bonds in the carbon side-chain with one chiral 
centre [27]. This unique property somehow increases the efficiency of tocotrienols 
in its metabolic function; it allows a better penetration of saturated fatty layers by 
tocotrienols as compared to tocopherols. Figure 1 above illustrates the difference 
between the structures of tocopherols and tocotrienols [28].
3. Sources of vitamin E
Vitamin E occurs naturally in vegetables, plants and plant oils. With regard 
to tocopherols, α-tocopherol is generally found in green leafy plants while 
γ-tocopherol occurs in the non-green parts of the plants, notably seeds and fruits 
[29]. Based on the United States Department of Agriculture nutrient database, 
α-tocopherol is commonly found in almonds, avocados, hazelnuts, peanuts and 
sunflower seeds; β-tocopherol in oregano and poppy seeds; γ-tocopherol in 
pecans, pistachios, sesame seeds and walnuts; and δ-tocopherol in edamame and 
raspberries. Both α-tocopherol and γ-tocopherol are present in food oils such as 
corn, peanut and soybean oil. Conversely, tocotrienols are rarely found in food 
sources or vegetable oils, with rice bran and palm oil being the only known excep-
tions. This explains the scarcity of scientific literature on tocotrienols compared 
to tocopherols as a form of vitamin E that is widely accepted by the public. In 
fact, most people are unaware that up to 70% of vitamin E from crude palm oil 
consists of tocotrienols [30, 31]. Studies have proven that the extraction of crude 
palm oil (scientifically known as Elaeis guineensis) can yield up to 800 mg/kg of 
tocotrienols in the form of α-tocotrienol and γ-tocotrienol [32]. Moreover, cereal 
grains such as barley, oat, rice, rye and wheat contain a higher concentration 
of tocotrienols than tocopherol in a ratio of 79:21, 77:23, 67:55, 51:49 and 55:45 
respectively [24]. However, in food supplements, tocotrienols are often prepared 
in soft-gel capsules. Even at a dose of 1000 mg daily, this is equivalent to a daily 
intake of 16.7 mg of tocotrienol/kg/day for a 60-kg person, or about seven times 
below the level where no adverse effects were observed in rats [33]. Hence, the 
usual dosage for any experimental use in humans has always been 400 mg daily in 
two divided doses which is a safe dosage with no observable adverse effects on any 
study patients to date.
4. Bioavailability and pharmacokinetics of vitamin E
Compelling evidence from recent research prove that tocotrienols are detected 
at appreciable levels in the plasma after supplementation, whether this was done on 
a short-term or long-term basis [34]. While both compounds are basically bioavail-
able, tocotrienol has a shorter plasma half-life [33]. One study showed that the half-
life of α-, γ- and δ-tocotrienols in human plasma was estimated to be 2.3, 4.4 and 
4.3 hours respectively [35]. However, the half-life of α-tocopherol and γ-tocopherol 
was 57 and 13 hours respectively [36]. Given that tocotrienols are essentially 
oil-based compounds, and that emulsions are known to increase the absorption of 
oil-based compounds based on the new system of self-emulsifying drug delivery 
system [37], new products such as Tocovid Suprabio™ were developed following 
this technique. This new product led to a threefold increase in the peak plasma 
concentration of α-tocotrienol in humans compared to a previous study [38]. It 
has also been shown that the bioavailability of tocotrienols is dependent on several 
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factors, food status being one of them. The mean apparent volume of tocotrienol 
distribution values is lower in the fed state, which means that the absorption is 
much better than in the fasting state [35]. Undoubtedly, tocotrienols have a very 
different pharmacokinetics from tocopherols which remain longer in the blood-
stream. However, the biodistribution of tocotrienols pointed to the accumulation 
of the compound in the vital organs [34]. Therefore, tocotrienols would score high 
in terms of therapeutic efficacy since this requires not only bioavailability but also 
presence in the target organs.
5. Vitamin E as an anti-oxidant
One of the most well-known effects of vitamin E is its anti-oxidant capability in 
inhibiting the peroxidation of lipids after its incorporation into the cellular membranes 
[39]. It is well documented that tocotrienol scavenges the chain propagating the per-
oxyl radicals [39]. Indeed, α-tocotrienol has a much stronger anti-oxidant effect than 
α-tocopherol. This superiority is due to a more even distribution of α-tocotrienol in 
the plasma membrane as a result of a more efficient collision of α-tocotrienol with the 
radicals. Compared to tocopherols, tocotrienols also have a higher recycling efficiency 
thanks to their chromanoxyl radicals [39]. These anti-oxidant properties of tocotrienol 
have a lasting impact on health in general. For instance, patients with hyperlipidae-
mia and carotid stenosis have been shown to demonstrate a significant reduction in 
thiobarbituric-acid-reactive substances that were related to platelet peroxidation. It is 
also proven that tocotrienols have the ability to scavenge free radicals that cause DNA 
damage, hence providing protection especially to the older age group [40].
6. Preventing cardiovascular diseases
One of the most feared ailments is cardiovascular disease, and with 17.9 million 
deaths every year, the World Health Organization (WHO) considers it the main 
cause of death globally [41]. WHO estimated that out of five mortalities from 
cardiovascular diseases, four were caused by heart attacks and strokes, with almost 
a third of these deaths occurring in people less than 70 years of age [41]. Among the 
modifiable risk factors of atherosclerosis that cause heart attacks are hyperlipidae-
mia, hypertension, diabetes mellitus and thrombosis. Given its ability as a lipid-
lowering, blood pressure-lowering, anti-diabetic and anti-thrombogenic agent, the 
effects of vitamin E – especially tocotrienol – deserve a thorough investigation.
6.1 Prevention of atherosclerosis
Atherosclerosis is considered the most important event that leads to heart 
attack and stroke as a result of abnormal deposits of lipids, cholesterol and plaque 
build-up. Animal studies have been conducted in rabbits to look at the microscopic 
development of atherosclerosis and lipid peroxidation. After ten weeks of treatment 
with tocotrienol-rich fraction (TRF) which normally consists of 80% tocotrienol 
and 20% tocopherol, the researchers [42] found that the cholesterol-fed rabbits had 
a lower content of malondialdehyde (MDA) or modified low density lipoprotein – a 
diagnostic biochemical marker for atherosclerosis. The rabbits also had less intimal 
thickening, while their internal elastic lamina was better preserved compared 
to those fed on a normal diet. Another study [43] showed that atherosclerosis is 
prevented through the modulation of the peroxisome proliferator-activated recep-
tors (PPAR) when TRF is administered. A different study [44] found that, after 
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being given TRF, subjects undergoing chronic haemodialysis showed improvement 
in their high-density lipoprotein (HDL), triglycerides and total plasma cholesterol 
as compared to placebo. All these studies prove that TRF intake essentially improves 
the lipid profiles, thereby preventing atherosclerosis.
6.2 Protection against reperfusion injury
Another important issue is related to myocardial ischaemia reperfusion injury. 
This happens when blood flow is restored to an infarcted myocardium either via 
percutaneous transluminal coronary angioplasty or bypass surgery. Restoring the 
blood flow, a process known as reperfusion, could also cause injury to the heart 
muscles and is therefore termed as myocardial ischaemia reperfusion injury. 
Reperfusion injury could account for almost 50% of the final size of myocardial 
infarction [45]. Almost all isoforms of tocotrienol have been shown to have car-
dioprotective effect. Nonetheless, γ-tocotrienol is demonstrably the most potent 
in myocardial ischaemic injury model. This particular study [46] shows that the 
interaction between mitogen-activated protein kinase (MAPK) with caveolin and 
proteasome plays an important role in the cardioprotective effect of tocotrienol that 
is achieved by altering the availability of pro-survival and anti-survival proteins.
6.3 Reduction of thromboembolic events
The discussion on this topic would be incomplete without any mention of 
thromboembolic events. In one animal study on dogs [47], an injection of intrave-
nous tocotrienols and tocopherols was administered; it was noted that the cyclic 
flow that measures the acute platelet-mediated thrombus formation and collagen-
induced platelet aggregation was significantly reduced in those receiving tocotri-
enol compared to those injected with tocopherol.
All these data suggest that tocotrienols provide better cardioprotective 
effect than tocopherols insofar as myocardial infarction, stroke or thrombosis is 
concerned.
7. Lipid-lowering effect
Studies on the hypercholesterolaemic properties of tocotrienols have gained 
traction after it was shown that the addition of tocotrienols significantly lowered 
the cholesterol level [48]. This effect was mediated by the inhibition of HMG-CoA 
reductase by post-transcriptional suppression of the enzyme itself by tocotrienols 
[49]. Indeed, γ-tocotrienol has been observed to have a dramatic 30-fold activity 
in inhibiting HMG-CoA reductase [50]. A later study further indicated that the 
American Heart Association Step 1 diet and TRF25 (25–200 mg/day) from rice bran 
could reduce the total cholesterol, LDL, triglycerides, and also apolipoprotein B in 
hypercholesterolaemic patients [51]. Another study demonstrated that when 30 mg 
tocotrienols are mixed with 270 mg flavonoids, the total serum cholesterol level, 
LDL, triglycerides and apolipoprotein B are also reduced in hypercholesterolaemic 
patients [52]. Furthermore, hypercholesterolaemic patients with non-alcoholic 
fatty liver disease who were treated with mixed-tocotrienols showed a higher 
percentage of normal liver echogenic response [53]. A study on atherogenesis 
using human monocyte-macrophages showed that α-tocotrienol, like the new 
compound FeAOX-6 which combines both the anti-oxidant structural features of 
tocopherols and carotenoids, reduced the cholesterol accumulation in the cells, with 
α-tocotrienol having a more potent effect [54].
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8. Anti-diabetic effect
Diabetes mellitus – which has risen dramatically in all countries irrespective 
of their income levels – is a chronic metabolic disease characterised by elevated 
blood sugar level that could affect the eyes, kidneys and nerves in the long run. 
While Type II diabetes develops when the body becomes resistant to insulin, Type 
I diabetes arises when the pancreas produces less or no insulin at all. According to 
current WHO estimates, approximately 422 million people worldwide suffer from 
diabetes [55]. Indeed, about 1.6 million deaths are attributed to diabetes on a yearly 
basis [55]. Alarmingly, these dismal numbers have been growing steadily in the last 
few decades.
Studies on the antidiabetic effects of vitamin E were conducted as early as the 
1990s to determine any possible association between vitamin E and diabetic risks 
[56–58] as well as the correlation between the dietary intake of vitamin E and 
insulin action [59, 60]. In a 2004 study with a very long follow-up, it was demon-
strated that the intake of vitamin E reduces the risk of Type II diabetes onset [61]. It 
was also found that TRF reduces the total cholesterol level, low-density lipoprotein 
(LDL) and total plasma lipid in diabetic patients [62]. Patients who were given 
canola oil enriched with tocotrienol also showed a significant reduction in their 
urine microalbumin and the serum C-reactive protein (CRP) known for its protec-
tive effect on the kidney and against nitrosative stress [63]. In an animal model, it 
was observed that both TRF and α-tocopherol improved the vascular endothelial 
function in streptozotocin-induced diabetic rats through their sparing effect on 
endothelium derived nitric oxide bioavailability [64]. Another study determining 
the effects of TRF on erythrocyte membranes and leukocyte deoxyribonucleic acid 
(DNA) damage in streptozotocin-induced diabetic rats revealed that daily supple-
mentation of tocotrienol for four weeks could inhibit lipid peroxidation while 
increasing the level of antioxidant markers [65]. In an animal study on the cognitive 
function and neuroinflammatory cascade in streptozotocin-induced diabetes, it was 
shown that the administration of tocotrienol significantly prevented behavioural, 
biochemical and molecular changes associated with diabetes. This points to the 
potential benefit of tocotrienol in preventing diabetic encephalopathy [66].
8.1 Preventing diabetic nephropathy
Diabetic nephropathy is a common complication of both Type I and Type II 
diabetes. Diabetic nephropathy (also called clinical nephropathy, proteinuria or 
microalbuminuria) is defined by the presence of protein of >0.5 g/24 h in the urine 
[67] and it increases the risk of death. In an animal study [68] designed to investi-
gate the impact of tocotrienol in streptozotocin-induced diabetes in terms of renal 
function and reno-inflammatory cascade, it was found that tocotrienol has a more 
profound effect than tocopherol in preventing biochemical and molecular changes 
associated with diabetes [68]. It was concluded from the study [68] that tocotrienol 
modulates the release of pro-fibrolytic cytokines, apoptosis, the ongoing inflamma-
tion, and the associated oxidative stress, which confers a renoprotective effect on the 
kidneys. Another study [69] was designed to determine whether TRF from palm oil 
(PO) or rice bran oil (RBO) could improve the renal function of rats as a result of 
their hypoglycaemic and anti-oxidant effect. The results analysed the fasting blood 
glucose, glycosylated haemoglobin, renal function biological markers, and oxida-
tive stress in the serum and urine of the rats. It was revealed that both palm-oil TRF 
(PO-TRF) and rice bran oil TRF (RBO-TRF) significantly improved renal function 
and glycaemic status, although PO-TRF conferred a better efficacy than RBO-TRF 
[68]. Hence, it was concluded that PO-TRF was more effective as a neuroprotective 
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and hypoglycaemic agent compared to RBO-TRF [69]. Another study [70] revealed 
that TRF ameliorated lipid induced nephropathy in type-II diabetes by modulating 
the TGF-β – besides leveraging on its hypoglycaemic, hypolipidaemic and antioxi-
dant properties – in order to prevent the increased expression of collagen type IV 
and fibrinogen. A recent prospective, randomized double-blind study [71] that was 
conducted to assess the effect of tocotrienol-rich vitamin E on diabetic nephropathy 
found that it attenuates the progression of diabetic nephropathy. It was also observed 
that a 12-week supplementation with tocotrienol-rich vitamin E led to a statistically 
significant improvement in renal function despite having no effect on glycaemia [71].
8.2 Preventing diabetic retinopathy
One of the most common complications of diabetes mellitus is diabetic reti-
nopathy which could lead to blindness in severe cases [72]. It is estimated that the 
prevalence of diabetic retinopathy worldwide is about 35%, with approximately 
10% of the world population afflicted with a vision-threatening disease [73, 74]. 
A strong correlation has been established between chronic hyperglycaemia and 
poor diabetic control with diabetic retinopathy [75]. Indeed, with the incidence 
of diabetes mellitus rising worldwide [76], a concomitant increase in diabetic 
retinopathy is to be expected [77]. A characteristic feature of diabetic retinopathy 
is retinal microvascular changes accompanied by an earlier neurodegeneration 
[78]. Oxidative stress, which induces hyperglycaemia, is considered as one of the 
main factors responsible for microvascular complication in diabetes mellitus [79]. 
Hyperglycaemia triggers cellular events resulting in inflammatory cytokines reac-
tions that in turn accelerate microvascular changes [80]. Another important event 
is angiogenesis, an over-expression of vascular endothelial growth factor (VEGF) 
associated with neurodegeneration and diabetes-induced oxidative stress [81]. As 
mentioned earlier, antioxidants confer their benefit in oxidative stress-induced dis-
eases, including diabetic retinopathy [82, 83], by scavenging free radicals through 
the hydrogen atom situated at the chromanol ring [84]. Indeed, a recent study [85] 
on streptozotocin-induced diabetic retinopathy in rats alluded to the beneficial 
effect of tocotrienol in preventing retinal neurodegenerative changes; it was shown 
that TRF prevented diabetic-induced changes in retinal layer thickness, retinal cell 
count, retinal cell apoptosis and retinal expression of VEGF.
8.3 Preventing diabetic neuropathy
One of the complications faced by almost 26% to 53% of diabetic patients 
worldwide is diabetic peripheral neuropathy [86, 87] that significantly impairs their 
quality of life [86]. The total cost of diabetic care [88] is around 4.2-fold higher 
among diabetic patients with neuropathic pain [89]. The mainstay treatment for 
managing diabetic neuropathy surely lies in glycaemic control and pain manage-
ment [88]. To that end, various pharmacological agents [90, 91] have been used, but 
they are all limited either by their adverse effects or by having no effect at all on the 
pathway of the neuropathic pain [92]. It is believed that oxidative stress plays a role 
in the pathogenesis of peripheral neuropathy [93]. One animal study with diabetic 
rats has shown that neuropathic pain is reversed by tocotrienols via the modulation 
of oxidative-nitrosative stress, caspase-3, and inflammatory cytokine release [94]. 
Another prospective study [95] on human subjects was aimed at evaluating the pro-
tective effect of mixed tocotrienol on the white matter lesion (WML) that reflects 
neurodegenerative changes; it was shown that subjects who received 200 mg of 
mixed tocotrienols twice daily for two years have attenuated progression of WMLs 
compared to placebo [95]. However, a recent study by the investigators of the 
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Vitamin E in Neuroprotective Study (VENUS) [96] found that the supplementation 
of oral mixed tocotrienols of 400 mg daily on diabetic patients with neuropathic 
pain did not show any remarkable improvement in alleviating the neuropathic 
symptoms. Nonetheless, the researchers qualified their statement by saying that 
their observation on the lancinating pain among the subsets of patients studied 
would require further exploration. More optimistically, a more recent randomized-
controlled study [97] on the effects of tocotrienol on diabetic neuropathy showed 
that supplementation of tocotrienol-rich vitamin E of 200 mg twice daily led to 
a higher serum nerve growth factor (NGF) and improved the nerve conduction 
velocity for all nerves tested after eight weeks of supplementation. The researchers 
concluded that TRF could be a disease-modifying agent that targets the NGF in 
improving nerve conduction velocity [97].
9. Preventing neurological diseases
Neurodegenerative diseases have been widely believed to be caused by oxidative 
damage due to reactive oxygen species [98]. Indeed, the increased levels of oxidative 
stress have been associated with numerous pathophysiological conditions together 
with derangements in mitochondrial complex I activity [99, 100]. Since vitamin E 
is a potent anti-oxidative agent, it is hypothesised that the neuroprotective effects 
of vitamin E is mediated via its anti-oxidative property [101]. A growing body 
of evidence supports the view that tocotrienol is a potent neuroprotective agent 
against Alzheimer’s disease [102]. However, as it stands today, the pathogenesis 
of Alzheimer’s disease remains unclear with a few different hypotheses [103]. 
Nonetheless, the ability of tocotrienol in reducing oxidative stress and promoting 
cellular repair contributes to its positive and beneficial effect in protecting the 
neurons. Admittedly, no clinical trials are available to support the hypothesis that 
tocotrienol could prevent Alzheimer’s disease, with available data based on only 
four human epidemiological studies [104–107]. With more studies in the future, 
this research gap could certainly be narrowed. Figure 2 below summarizes the 
 possible pathways for the neuroprotective actions of tocotrienol.
Figure 2. 
A summary of the current in vitro evidence of neuroprotective actions of tocotrienol. Legend: Solid line 
represents beneficial effects of tocotrienol on neurons. Dotted line represents potential adverse effects of 
tocotrienol on neurons.
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10. Preventing bone diseases
Osteoporosis, a metabolic bone disease requiring extensive healthcare, is common 
in both men and women, though women suffer fragility fracture from osteoporosis at 
a ratio of 6:1 to men [108]. Osteoporosis is caused by an imbalance in bone remodel-
ling, where the rate of bone resorption is faster than bone formation [109]. While it is 
known that menopause in women leads to oestrogen deficiency, in men, however, it is 
due to late-onset testosterone deficiency [110, 111]. The existing therapies for osteo-
porosis include bisphosphonates, teriparatide and strontium ranelate, all of which 
increase bone mineral density [112]. Recent studies have tried to explore the use of 
natural products to cure osteoporosis. With its inherent antioxidative and anti-inflam-
matory properties that are implicated in the pathogenesis of osteoporosis, tocotrienol 
is an agent of choice for such studies [113, 114]. Oxidative stress is known to damage 
osteoblasts by affecting both its differentiation and survival [115]. Oxidative stress 
also affects the signalling of osteoclasts and promotes the differentiation process [116]. 
Similarly, proinflammatory cytokines such as tumour necrosis factor (TNF), inter-
leukin 1 (IL-1), and interleukin-6 (IL-6) promote osteoclasts differentiation [117]. 
The expression of proinflammatory cytokines is also suppressed by tocotrienol [118]. 
Hence, it is reasonable to assume that by reducing both oxidative stress and inflamma-
tion, the process of osteoporosis could be mitigated, if not prevented, by tocotrienol. 
A study on bone histomorphometry [119] that describes the bone volume and tra-
becular number, thickness and separation showed that palm tocotrienol preserved the 
trabecular bone structure, volume, and trabecular separation in rats with ovarian defi-
ciency from ovariectomy. It was also demonstrated in another study [120] that in the 
bone loss model of rats, palm tocotrienol decreased the eroded surface and increased 
the osteoblast number, osteoid surface and osteoid volume in the supplemented 
study animal as compared to the other arm of the study. In another experiment on 
ovariectomised rats [121], the group that was treated with palm vitamin E showed 
significantly higher bone mineral density at the femur and vertebrae compared to the 
untreated group. The bone calcium level at the femur and vertebra of orchidectomised 
and ovariectomised was also found to be restored with palm vitamin E supplementa-
tion [122, 123]. Nonetheless, while tocotrienol has been proven to improve bone 
density and microarchitecture, and enhance bone biomechanical strength, the study 
[124] done was not convincing enough to show any statistical difference. The effects of 
tocotrienol on the bone are summarised below in Figure 3 [125].
Figure 3. 
The effects of tocotrienol on bone histomorphometry, bone mineral and bone calcium content.
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Let us now look at the mechanism of actions of tocotrienol in the prevention of 
osteoporosis. Studies have revealed that oxidative stress plays a major role in the devel-
opment of osteoporosis [126, 127]. Any increase in the oxidative stress process would 
lead to a decrease in differentiation of osteoclasts [128] as well as the bone resorption 
activity [129], which would subsequently impair the musculoskeletal system. Some 
in vivo studies [124, 130] which supplemented the study rats with tocotrienol showed 
a reduction in oxidative stress and anti-oxidant enzyme activities such as malondi-
aldehyde. Additionally, an in vitro study [131] showed that γ-tocotrienol homologue 
decreased the oxidative damage on primary osteoblast culture. Tocotrienol exerts 
its effect by preserving the antioxidant enzyme activities in bone cells affected with 
oxidative stress [132]. Another effect is via the mevalonate pathway which is known 
to regulate osteoblastogenesis and osteoclastogenesis [133]. Tocotrienol suppresses 
the mevalonate pathway via the hydroxy-methyl-glutaryl-coenzyme A (HMG-CoA) 
reductase, an enzyme that is also involved in cholesterol synthesis [134]. Another 
study [135] further revealed that tocotrienol, in combination with statins, enhances 
bone static histomorphometry and remodeling markers in the ovariectomised rats 
although it could not be confirmed whether this was via the mevalonate pathway 
alone or if it involved some other pathways as well. The anti-inflammatory effect of 
tocotrienol in preventing proinflammatory cytokines such as IL-1 and IL-6 has also 
been shown to preserve bone health in rats [120, 136, 137]. It is worth noting that the 
differentiation and activity of osteoclasts and osteoblast are governed by some genes 
[138] and that supplementation of palm vitamin E has been shown to significantly 
enhance the gene expression [139]. Another study [140] demonstrated that tocot-
rienol could enhance the gene expression related to bone formation and osteoblast 
activity. All the above-mentioned studies confirmed that tocotrienol possesses some 
promising bone-protective effect: it increases the osteoblast number, mineral deposi-
tion and bone formation; and it reduces the osteoclast number, thereby preventing the 
bone resorption, erosion, and degeneration of bone mineral density and microarchi-
tecture. The summary of the whole mechanism is illustrated in Figure 4 below.
Figure 4. 
The bone protective mechanism of Tocotrienol.
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11. Preventing autoimmune diseases
One of the most common autoimmune diseases is rheumatoid arthritis. With a 
prevalence of about 0.5 to 1.0% worldwide [141], it is presented as a typical sys-
temic autoimmune disease of unknown aetiology that affects many joints [142]. The 
joint inflammation is characterised by some marked changes in the cartilage from 
the effects of proinflammatory mediators such as cytokines and C-reactive protein 
[143]. These include destruction of cartilage [144], leukocytes infiltration [145], 
and bone erosion [146]. The proinflammatory cytokines such as tumour necrosis 
factor-α (TNF-α), Interleukin-1α (IL-1α) and IL-1β [147] play a role in modulating 
inflammatory responses in the affected joints [148]. These cytokines have been 
shown to be involved in the pathogenesis of rheumatoid arthritis in animal studies. 
Since such studies closely mimic human disease [149], the development of biologi-
cal agents that have the potential to modulate the cytokine mediators could yield an 
effective prevention against rheumatoid arthritis [150]. It has been demonstrated in 
an animal study [151] that palm γ-tocotrienol exerts an effect against both oxida-
tive stress and joint pathology. In another study [152], it was discovered that palm 
δ-tocotrienol somehow reduced inflammation in arthritic rats. This should not be 
surprising given that palm tocotrienol has been shown to downregulate proinflam-
matory cytokines such as TNF-α, IL-1α, IL-β, IL-6 and IL-8 [153]. In another recent 
study [154] on the temporomandibular joint (TMJ) of a rat model, it was observed 
that in the group fed with TRF, the bone mineral density was notably increased. The 
researchers concluded that the concomitant decrease of plasma level of inflamma-
tory cytokines with the increased bone density is sufficient evidence that TRF could 
be used in the management of TMJ rheumatoid arthritis.
It is also pertinent to look at another common ailment: bronchiole asthma. 
This chronic respiratory problem with a female preponderance afflicts more than 
339 million people worldwide, according to a WHO estimate [155]. An increase 
in antinuclear antibodies and autoantibodies against bronchial epithelial antigens 
or endothelial antigens suggest that asthma is an autoimmune disease [156]. As 
the first experiment to demonstrate the effectiveness of tocotrienol in preventing 
asthma, a study [157] on rats showed that γ-tocotrienol possesses better free radical-
neutralizing activity in vitro; reduces the eosinophil and neutrophil counts in vivo; 
and promotes lung-endogenous antioxidant activity. Another study investigated the 
effect of tocotrienol on airway remodelling [158], undoubtedly one of the charac-
teristic features of asthma. It was shown that several inflammatory mediators were 
involved in airway remodelling [159, 160] and the most important among them is 
transforming growth factor beta1 TGF-β1 [161, 162]. The researchers convincingly 
proved the effect of γ-tocotrienol on the TGF-β1 induced differentiation of human 
airway smooth muscle and the extracellular deposition and the down-signaling of 
the airway smooth muscle cells activated by TGF-β1 [158]. This study suggested 
that γ-tocotrienol could play a therapeutic role in regulating airway remodelling in 
asthmatic patients.
12. Gastroprotective effect
Non-steroidal anti-inflammatory drugs (NSAIDs) are probably the most 
frequently used therapeutic agents in the world [163] for the treatment of pain, 
arthritis and trauma, besides many other indications. Achieving more than 73 
million prescriptions per year [164], NSAIDs have been notoriously associated with 
gastrointestinal bleeding [165]. In an earlier study on a rat model of three differ-
ent study groups [166], it was found that both TRF and tocopherol were equally 
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effective in preventing aspirin-induced gastric ulcer. In another recent study [167] 
on a rat model comparing control to a group fed with omeprazole and another 
group with tocotrienol, it was discovered that while both groups were effective 
against gastric ulcer, the tocotrienol group displayed various modes in its protective 
effect – via the nitric oxide (NO) pathway and superoxide dismutase (SOD) activity 
– and in reducing TNF-α activity.
13. Radioprotective effect
With the increasing adoption of radiation in both clinical and non-clinical 
applications [168], human exposure to radiation is set for an exponential increase. 
Radiation toxicity is manifested in oxidative stress and DNA damage [169], inflam-
matory changes [170] and cell apoptosis [171]. Studies were carried out to examine 
the potential benefits of naturally occurring products such as vitamin E, a potent 
anti-oxidant with the capacity to neutralize free radicals from radiation exposure 
by donating H atoms [172]. It was shown that exposure to ionizing radiation yields 
reactive oxygen species (ROS) and nitrogen species (RNS), hydroxyl radical, 
superoxide, peroxynitrite and hydrogen peroxide. These reactive species of ROS 
and RNS with radiation-induced radicals damage proteins, DNA and lipids, besides 
activating intracellular signalling pathways that release cytochrome C from the 
mitochondria, eventually leading to cell apoptosis [173–175]. Thanks to its potent 
anti-oxidant properties, tocotrienol has been a subject of several studies and has 
been reported to be radioprotective [176–178]. Studies on a rat model [176, 179] 
have showed the protective effect of γ-tocotrienol against radiation-induced DNA 
damage through the activation of haematopoietic progenitors, red and white blood 
cells including platelets, and also through the inhibition of 3-hydroxy-3-methylgl-
utaryl-CoA Reductase (HMG-CoA Reductase) – a protein-coding gene-mediated 
nitrosative stress [180]. It is also proven that γ-tocotrienol increases serum IL-6 and 
granulocyte colony stimulating factor (G-CSF), both of which induce haematopoie-
sis and are protective against radiation-induced neutropenia and thrombocytopenia 
in mice [181].
14. Anti-cancer effect
Cancer (also known as malignant tumours or neoplasms) is the second leading 
cause of mortality globally according to WHO [182], with an estimated 9.6 mil-
lion deaths in 2018. The cancer burden keeps on growing inexorably, exerting its 
pressure emotionally and financially on individuals and families, not to mention 
the community and health system. While chemotherapy has been the mainstay of 
treatment, it is limited by a few factors such as tumour immune evasion [183, 184], 
drug toxicity and resistance, and inappropriate cancer metabolism [185], all of 
which lead to possible metastases and recurrence. Hence the search for a more 
effective and potent anti-cancer agent. Buoyed by the earlier success in extract-
ing anti-cancer agents from plants, the search has been on for a natural product. 
Tocotrienol became the choice of study due to its multitargeted actions in destroy-
ing cancer cells, promoting cancer cells apoptosis and inhibiting angiogenesis and 
metastases [186–188]. It is certainly beyond the scope of this writing to discuss all 
the research conducted on the effects of tocotrienol on cancer. Notable among the 
most recent research papers on this subject are “Tocotrienols and Cancer: From the 
State of Art to Promising Novel Patents” [189] and “Tocotrienols Modulate a Life or 
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Death Decision in Cancers” [190]. For our purpose, it suffices to understand how 
tocotrienol exerts its anti-cancer effect. The mechanism of action is illustrated in 
Figure 5. Indeed, the effect of tocotrienol in suppressing the growth of different 
form of malignancies, including that of the uterine, ovary, prostate, liver, gastric, 
breast and brain, is well documented [191, 192]. Figure 5 below depicts the possible 
mechanism of actions of tocotrienols in exerting its anti-cancer effect [193].
14.1 Apoptosis
As an innate defence mechanism against cancer, apoptosis is considered critical 
[194, 195]. Natural molecules have the potential to exert their apoptosis-inducing 
quality [196–199] and tocotrienols are one of those compounds that could exert 
the anti-neoplastic activity via this apoptosis mechanism [200]. One study [201] 
demonstrated that γ-tocotrienol caused substantial apoptosis in tumour cells by 
down-regulating several oncogenic gene products’ expression. It also displayed che-
mosensitisation and anti-invasive properties against prostate cells [202], and induced 
apoptosis in gastric cancer cells [203]. In another study [204], both α-tocopherol and 
γ-tocotrienol showed anti-proliferative activities and apoptosis on both the cervical 
carcinoma and hepatoma cell lines. Tocotrienols were also found to induce apoptosis 
in breast cancer cell lines [205] and effected both apoptosis and antiangiogenic activ-
ity of murine mammary cancer cells in mice [206]. A different study revealed that 
δ-tocotrienol is more efficacious than both α- and γ-tocotrienol in exerting its apop-
tosis effect on both human lung adenocarcinoma and glioblastoma [207]. In a study 
[208] on human bladder cancer cells, δ-tocotrienol was observed to have effectively 
induced apoptosis and chemosensitization, in addition to arresting the growth of 
human bladder cells. A study conducted on human chronic myeloid leukaemia cells 
[209] found that γ-tocotrienol was an effective inducer of apoptosis in the myeloid 
leukaemia cells. TRF mixture is also found to prevent cell proliferation, migration, 
and tumour cell invasiveness by inducing apoptosis in non-small cell lung cancer 
Figure 5. 
Anti-cancer mechanism of actions of tocotrienol.
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cells (NSCLC) [210]. Furthermore, γ-tocotrienol exerted its anti-proliferative effect 
and induced apoptosis in human cervical cancer cells [211].
14.2 Cell cycle arrest
Cell cycle has its checkpoints from one phase to another, and any aberrant 
activation may lead to the proliferation of tumour cells. Hence, it is imperative to 
target these checkpoints in cancer therapy [212]. The cell cycle and its checkpoints 
are illustrated in Figure 6 below [213].
It is worthy of note that γ-tocotrienol had an effect on the G2/M arrest and apop-
tosis of breast cancer cells, with the potential to reverse multi-drug resistance [214]. 
Another study on brain cancer cells [215] documented the anti-proliferative effect 
of γ-tocotrienol in combination with another agent, jerantinine (an indole alkaloid 
obtained from leaves extract) which led to G0/G1 cell cycle arrest. The combination 
effect of γ-tocopherol and δ-tocotrienol was also cited in successfully arresting the 
G1 phase and G2/M phase in the cell cycle of prostate cancer cells [216], besides 
inhibiting prostate cancer cell growth. A synergistic effect was observed between 
δ-tocotrienol and geranylgeraniol (a compound synthesised endogenously in the 
human body via mevalonate pathway) in arresting G1 phase activity in prostate 
carcinoma cells [217]. With the addition of γ-tocotrienol, the cell cycle at G0/G1 
phase was also arrested while the S phase was reduced in cervical cancer HeLa cells 
[211]. In short, tocotrienols, whether alone or in combination with other agents, are 
capable of exerting their inhibitory effects through the checkpoints in the cell cycle. 
This promising evidence supports their future development as therapeutic agents in 
modulating the checkpoints of the cell cycle.
14.3 Anti-angiogenesis
Angiogenesis, defined as the formation of new blood vessels, is an important process 
for tumour growth and metastases [218] triggered by chemical signals from tumour 
Figure 6. 
The cell cycle and its checkpoints. There are four phases in the cell cycle – G1 phase, S-phase, G2-phase, and 
M-phase. The checkpoints control the progression of the cell cycle which is unidirectional in nature.
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cells. Researchers have identified more than a dozen angiogenic activators, including 
vascular endothelial growth factor (VEGF) which is a powerful angiogenic factor in 
neoplasms as well as normal tissue [219]. Therefore, targeting these angiogenic fac-
tors seemed to be the most rational intervention to combat tumour growth [220, 221]. 
Several trials [222–224] have shown the effectiveness of tocotrienol in inhibiting 
angiogenesis in various cancers, with the process illustrated in Figure 7 below [225].
A study has shown that both δ- and γ-tocotrienol inhibit angiogenesis and prolif-
eration in human hepatocellular carcinoma cells [226]. In another study, it was dem-
onstrated that δ-tocotrienol inhibited tumour angiogenesis via VEGF and MMP-9 in 
pancreatic cancer cells; it also decreased the expression of cell surface markers in cancer 
stem cells [227]. Another study revealed that δ-tocotrienol exhibited potential against 
both melanoma and its associated stem cells [228, 229], while displaying suppressive 
action on prostate cancer stem-like cells [230]. Recent findings also indicated that 
tocotrienols displayed antiangiogenic protein expression of VEGF in colorectal cancer 
[231], malignant mesothelioma [232], breast cancer [233], ovarian carcinoma [234], 
and head and neck squamous cell carcinoma [235]. All these studies provide ample evi-
dence of the role of tocotrienol in arresting tumour growth by inhibiting angiogenesis.
14.4 Anti-metastasis
The morbidity and mortality from cancer are mainly caused by cancer metasta-
ses; in fact, almost 90% mortality is thought to be due to metastases [236]. Cancer 
metastasis starts at the primary tumour with the detachment of metastatic cells 
which then travel to different parts of the body either through the bloodstream or 
lymphatic drainage, and thereafter settle and start growing at the distal site [237]. 
To put it simply, the process of metastasis involves four essential steps: detachment, 
migration, invasion and adhesion. This is illustrated in Figure 8 below [238].
Figure 7. 
The angiogenic cascade. (A) During the process of angiogenesis, stable vessels undergo (B) a vascular 
permeability increase which allows extravasation of plasma proteins. (C) Degradation of the ECM by matrix 
metalloproteases (MMPs) relieves pericyte-endothelial cells (EC) contacts and liberates extracellular matrix 
(ECM)-sequestered growth factors. (D) ECs then proliferate and migrate to their final destination and (E) 
assemble as lumen-bearing cords.
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Cancer survival rate has improved significantly over the years from early 
diagnosis and inhibition of cancer growth. Nevertheless, the mainstay of cancer 
treatment for metastasis remains chemotherapy or radiotherapy. Tocotrienols have 
gained prominence in the last several years due to their anti-proliferative, anti-
angiogenic, anti-migratory and anti-metastatic properties as exhibited in vivo and 
in vitro data [239]. Indeed, for metastasis to occur, cancer cells need to detach and 
migrate to a distant target organ, a process followed by adhesion and local invasion 
[240]. The ability of tocotrienol in halting cell migration has been demonstrated in 
several studies [224, 241–243]. In one study on human umbilical vein endothelial 
cells (HUVEC), treatment with δ-tocotrienol suppressed VEGF-induced migration 
by 50% [224]. Another study proved a dose-dependent inhibition of non-small cell 
lung cancer (NCSLC) cells migration [241], while a different one demonstrated 
the ability of γ-tocotrienol in inhibiting in-vitro human gastric cells migration 
[242]. In another study on VEGF-stimulated HUVEC migration essay, it was found 
that γ-tocotrienol suppressed the migratory potential of the HUVEC cells [243]. 
After the cancer cells migration, the subsequent event in the process of metastases 
is cell adhesion and invasion; this is preventable by suppressing the tumour cell 
invasion after adhesion [242]. An in vitro study has shown that after being treated 
with δ-tocotrienol, a pancreatic cancer mouse model no longer displayed any 
signs of invasive cancer [244]. A previous study has also showcased the ability of 
γ-tocotrienol in halting the invasion of the prostatic cancer cells in the control group 
[202], thereby suppressing the main process in the perpetuation of metastasis.
14.5 Anti-oxidant
Oxidative stress refers to an imbalance of free radicals or reactive oxygen species 
(ROS) and antioxidants in the body [245]. This imbalance has been linked to a litany 
of chronic conditions including neurodegenerative disease, cardiovascular disease, 
diabetes mellitus, and many other pathologies such as cancer [246]. A variety of 
Figure 8. 
A schematic representation of the four stages of metastatic dissemination of cancer cells from the primary 
tumour into the blood circulation, involving detachment, migration, invasion and adhesion.
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deleterious modifications of macromolecular components such as DNA, lipids and 
proteins were due to this chronic oxidative stress [247]. There is also a possibil-
ity that ROS mediates an indirect attack on DNA, resulting in secondary reactive 
intermediates that would couple with the DNA bases to form DNA adducts [248]. 
This formation is central to what is known as carcinogenesis [249]. Oxidative lesions 
have been implicated in the aetiology of cancer due to the oxidative DNA damage 
[250–254]. It is now clear how carcinogenesis is perpetuated by this oxidative stress 
process, as illustrated in Figure 9 below [255].
Evidence from clinical and laboratory studies have showed that the elevated level 
of ROS contributed to both cancer initiation and cancer progression. Consequently, 
the most rational, if not preventive, approach is to use antioxidants for combating 
ROS [256]. Although the results regarding the use of dietary antioxidants were prom-
ising, research on this topic is still inconclusive and controversial [257]. Moreover, 
while studies have indicated that anti-oxidant supplementation resulted in an 
increase in survival rates and tumour response, with fewer toxicities than controls, a 
systematic review previously done on this topic showed no evidence of interference 
by antioxidants on chemotherapy mechanisms that conclusively proves that anti-
oxidants (such as vitamin E) improve tumour response rate or the patients’ survival 
[258]. Despite promising results on improving the side effects from chemotherapy or 
radiotherapy treatment of cancer, further research into anti-oxidants [259], espe-
cially vitamin E in general and tocotrienol in particular, is highly warranted.
15. Discussion
Long ignored despite being close yet superior to its related isomer tocopherol, 
tocotrienol is increasingly becoming a subject of interest in vitamin E research 
Figure 9. 
Oxidative stress mediating cancer development. Biological, chemical and physical factors mediated free 
radicals (ROS) which damage the biomolecules that initiate the neoplastic cells through the up-regulation 
of transcriptional factors and inactivation of tumour suppressor genes. They also alter the functions of DNA 
repair proteins, apoptotic modulators, metabolic enzymes and signalling pathways that induce the neoplastic 
condition.
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among the scientific community. One of the main reasons why it was understudied 
could be due to its abundant presence in palm oil, itself a much maligned product 
that had to bear the full brunt of a damaging smear campaign for decades. In fact, 
palm oil contains about 70% of all tocotrienol homologues namely α-, β-, δ- and 
γ-tocotrienols. Consequently, it would be no exaggeration to say that palm oil is 
nature’s best kept secret, if not the most promising natural substance in influencing 
health and disease.
Growing interest in tocotrienols has led to research exploring the molecular 
basis of their action in health. This chapter has highlighted the recent advances 
in this rapidly developing field of study. Indeed, recent studies have shown that 
tocotrienols may have superior chemopreventive or chemotherapeutic effects when 
used either alone or in combination with tocopherols. Indeed, tocotrienols are well 
adapted for their biochemical function. Thanks to their organic structure featuring 
a long-saturated carbon side-chain, they are able to penetrate more efficiently in 
the lipid membrane and in the intermembrane of tissues containing saturated fatty 
layers. This ability contributes immensely to their therapeutic efficacy.
Without doubt, the beneficial health effects of tocotrienols are partly related to 
their anti-oxidant activity. Though both tocotrienol and tocopherol have the ability 
to scavenge the free radicals directly by donating the phenolic hydrogen of their 
chromanol ring, tocotrienol is considered a better anti-oxidant due to its generally 
uniform distribution in the membrane bilayer coupled with a stronger disordering 
of its membrane lipid structure. Vitamin E, in particular tocotrienol, was shown to 
play a vital role in maintaining the integrity of the central nervous system through 
its anti-oxidant property. Indeed, as an organ with very high metabolic needs in 
terms of oxygen consumption, the brain is extremely susceptible to any forms 
of oxidative stress. However, current evidence is largely focused on Alzheimer’s 
disease – an age-related inflammatory neurodegenerative disease characterised 
by the presence of pathognomonic amyloid plaques and neurofibrillary tangles. It 
is postulated that the main mechanism of action of tocotrienol in attenuating the 
neurodegenerative changes is via its anti-oxidant action, either by inhibiting the 
production of ROS or by reducing the lipid peroxidation by-products. Admittedly, 
a gap still persists in this area insofar as other neurodegenerative conditions (such 
as Parkinson’s disease) are concerned. Notwithstanding the fact that some recent 
studies have reported contradicting outcomes on the relationship between tocotri-
enol and Parkinson’s disease, it is hoped that future studies will shed more light in 
this area.
Given the potential of tocotrienol in preventing auto-immune diseases, espe-
cially through its anti-inflammatory properties, the evidence available warrants 
further investigation into its molecular action. That would enable the development 
of drug targets to combat inflammatory diseases. Nevertheless, the therapeutic 
potential of tocotrienol as an anti-inflammatory agent cannot be denied. On the one 
hand, δ-tocotrienol somehow lessened joint inflammation in arthritic rats by reduc-
ing the level of proinflammatory cytokines. On the other hand, in a human study, 
γ-tocotrienol improved airway remodelling that characterises bronchiole asthma 
which is essentially an inflammatory disorder. Another rat model also showed that 
tocotrienol is effective against gastric ulcer. The gastroprotective effect of tocotri-
enol was mainly modulated through a reduction in inflammatory response, besides 
its anti-oxidative properties. Though this protective effect was witnessed in various 
animal models of gastric ulcer, clinical studies on the use of tocotrienol in patients 
with peptic ulcer disease or even gastritis are yet to be conducted.
As one of its health benefits, tocotrienol – through its ability to improve the lipid 
profiles – has been shown to confer a cardioprotective effect, at least with respect to 
atherosclerosis, myocardial infarction and thrombosis. There is sufficient evidence 
19
Tocotrienol: An Underrated Isomer of Vitamin E in Health and Diseases
DOI: http://dx.doi.org/10.5772/intechopen.96451
to prove that tocotrienol, especially in the form of γ-tocotrienol, is anti-cholester-
olaemic; this is achieved by inhibiting the mevalonate pathway responsible for the 
synthesis of cholesterol and other isoprenoids. Overall, the potential of tocotrienol 
as a potential hypocholesterolaemic agent is evidenced by in-vitro, in-vivo and 
human clinical trials. Thus, tocotrienol supplementation is highly recommended for 
patients suffering from hypercholesterolaemia.
In fact, human studies on the effects of tocotrienol on cardiovascular disease 
have been limited to its anti-hypercholesterolaemic property. The only exception is 
an ongoing clinical study at the National Heart Institute of Kuala Lumpur, Malaysia. 
Conducted by this author, it investigates the ability of tocotrienol in preventing 
atrial fibrillation in post-coronary artery bypass grafting surgery. Indeed, while 
tocotrienol has been shown to be protective against cardiovascular disease in animal 
models, its direct effects on humans are inconsistent. Our current evidence serves 
as a basis for further clinical trials aimed at validating the positive effects of tocotri-
enol especially among patients susceptible to cardiovascular complications.
The potency of α-tocotrienol as an anti-atherogenic agent, besides being a bul-
wark against cerebrovascular disease, is well documented. Several animal models 
have demonstrated that tocotrienol protects against ischaemic stroke by attenuating 
brain lesion volume. A similar scenario was observed during clinical trials where it 
was shown to attenuate the progression of brain white matter lesion. Consequently, 
it could be safely concluded that tocotrienol protects against cerebrovascular 
disorders.
Tocotrinol-rich vitamin E (TRF) has been observed to ameliorate diabetes in 
animal studies through its superior antioxidant, anti-hyperglycaemic and anti-
inflammatory properties. A recent clinical trial also showed that TRF significantly 
reduced serum creatinine level, and therefore has the potential to be used as a 
supplement in the treatment of diabetic nephropathy. Moreover, the anti-diabetic 
properties of tocotrienol in preventing nephropathy, retinopathy and neuropathy 
have been proven in several other studies.
Studies conducted on animal models have demonstrated that tocotrienol can 
mitigate, if not prevent, osteoporosis in rats by reducing oxidative stress and 
inflammation. Indeed, tocotrienol has been proposed to counter osteoporosis which 
leads to fragility fracture, a leading cause of morbidity and mortality worldwide. It 
is postulated that tocotrienol mediated bone protection via its anti-oxidant, anti-
inflammatory, mevalonate suppression and gene-modulating properties. Despite 
strong evidence in animal models showing improved bone structure and strength 
after tocotrienol supplementation, limited human clinical trials on the effects of 
tocotrienol on bone health has been a serious impediment to its clinical use.
The role of γ-tocotrienol in protecting against radiation toxicity has been a 
subject of numerous animal studies, and the results are very promising. With the 
widespread use of ionising radiation in various non-clinical applications such as 
construction, sterilization of food products and engineering, exposure to radia-
tion – whether intentional or unintentional – is very high. Studies have shown that 
γ-tocotrienol has a protective effect against radiation injury by increasing haema-
topoietic progenitors, neutrophils, platelets, white blood cells and reticulocytes. It 
has also been demonstrated that γ-tocotrienol protects against vascular injury by 
inhibiting HMG-CoA reductase. Since tocotrienols accumulate in the small intestine 
and colon at a higher level than tocopherols, they could protect the gastrointestinal 
tract from injury.
Last, but certainly not least, with cancer being one of the leading causes of death 
worldwide, the role of tocotrienol as an anti-cancer agent cannot be underesti-
mated. Tocotrienol has been shown to modulate intracellular signalling pathways; it 
induces apoptosis and cell cycle arrest, and inhibits angiogenesis, cell proliferation 
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and metastases. Compared to its isoform tocopherol, tocotrienol displayed superior 
activities in anti-cancer studies. Indeed, in a structural-activity relationship study, 
the chromanol ring and phytyl carbon tail played a major role in inducing cancer 
cell apoptosis. However, despite the abundance of cell and animal studies investi-
gating the role of tocotrienol, evidence regarding its preventive effects on cancer 
remain inconclusive, with most trials still at the preliminary stage. Nonetheless, our 
improved understanding of the mechanism of actions of tocotrienol in the sup-
pression of cancer cell growth by inhibiting proliferation, migration, and invasion 
should not be discounted; it will inform more targeted research into cancer therapy 
in the future.
16. Conclusion and future direction
This chapter has highlighted the wonders of tocotrienols which, thanks to 
their efficacy and safety profile, are attracting increased attention. Examining 
the latest research into tocotrienols, it has demonstrated the undeniable benefits 
of tocotrienols in conferring protection against cancer as well as a whole litany of 
diseases including cardiovascular, metabolic, autoimmune, bone and neurological 
diseases. Admittedly, many of the researches were conducted in the laboratory, 
with some preclinical trials translated into clinical trials. Nonetheless, it is hoped 
that more randomised clinical trials will be carried out on a global scale in the near 
future. From the vessels in the heart to neurons in the brain, tocotrienols have the 
 extraordinary potential to be the future of vitamin E research.
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